Janssen Global Public Health

Dr. Maik Stumpf, Director Disease Management Programs

Aug 31st 2015
Johnson & Johnson Worldwide Corporate Contributions

FOCUS AREAS

Saving and improving the lives of women and children

Preventing disease in vulnerable populations

Strengthening the healthcare workforce
Janssen Vaccines

FOCUS AREAS

Leading research efforts into life-saving vaccines, monoclonal antibodies and delivery technologies

Supplying affordable vaccines to the developing world through partnerships

Improving vaccine delivery to address unmet health needs
Our Focus

Janssen Global Public Health aims to build on our strong legacy of innovation and dedication to improving global health to make a difference for patients and advance healthcare in society all over the world.

Research & Development
Our research and development efforts focus on neglected diseases and medical needs that disproportionately impact public health.

Sustainable Access
We are creating new models for sustainable and affordable access to our medicines.

Collaboration
We partner to develop innovative solutions and policies that improve the health outcomes for individuals, families and communities.

Education & Prevention
We are empowering a new generation of healthcare workers & patients through training & disease management education.
Innovative R&D to Treat and Prevent Disease

FOCUS AREAS

- Fighting multi-drug resistant tuberculosis (MDR-TB)
- Developing new treatments for NTDs
- Investigating long-acting treatments for HIV
- Collaborating to prevent sexual transmission of HIV
Increasing Sustainable Access to Our Medicines

FOCUS AREAS

Providing sustainable access to HIV treatment in resource-limited settings

Planning toward future innovative access models for MDR-TB
HIV/AIDS Access Environment Today

Expanding access to HIV treatment is a top global public health priority in resource-limited settings.

In 2013, there were an estimated **2.1 million** new HIV infections globally and **1.5 million** AIDS-related deaths.

**12.9 million** PLWHA received treatment globally

**11.7 million** PLWHA receiving treatment live in low- and middle-income countries (LMICs)

**35 million** people living with HIV

**22 million** need HIV treatment*

*According to the World Health Organization’s 2013 treatment guidelines.
Our Approach to HIV Drug Access

Affordability
Licensing & Access Pricing

Availability
Priority Branded Registration

Appropriate Use
Medical Education

Adoption
Guideline Inclusion & WHO Prequalification
TB & MDR-TB: A Global Health Crisis

In 2013, 1.5 million people died from TB.

9 million people fell ill with TB.

33% of the world’s population is infected with the germ that causes TB.

If not diagnosed and appropriately treated, people ill with TB can infect 10 to 15 people over the course of a year.

480,000 new cases were estimated in 2013.

Only 20% of MDR-TB patients worldwide were enrolled in treatment.

Over 50% of MDR-TB cases occurred in China, India, and the Russian Federation.

20% in treatment.
Designing a Global TB Access Framework

With regulatory filings and approvals currently underway across the world, our Access & Affordability Strategy seeks to assure sustainable access through five key elements:

- **Registration efforts** by high disease burden to assure timely availability for patients in need
- **Innovative access partnerships & research collaborations** to advance new drug regimens and ensure responsible access to new healthcare solutions
- **Support of appropriate use** through responsible distribution in collaboration with international and national TB stakeholders
- **Differentiated pricing** which balances value & innovation, as well as affordability
- **Post-approval commitments** in R&D for continued treatment innovation including a Phase 3 program, pediatric formulation and patient registry
Collaboration

Partnerships are central to all that we do. We are committed to working across sectors with governments, donors, non-governmental organizations (NGOs), multilateral organizations, and other stakeholders to foster innovative approaches and increase access to new medicines and new technological solutions.
A Recognized Leader in Access to Medicines

J&J ranked #3 in the 2014 Access to Medicine Index, a comprehensive review of the global health access efforts of the top 20 research-based pharma companies.

We were acknowledged by the 2014 Index for:

- leading in development of “child-size” medicines
- piloting innovative financing models and equitable pricing strategies
- substantially expanding our pediatric drug donations in HIV and neglected tropical diseases
- introducing specific improvements for patients, including the first new drug for MDR-TB in 40 years and a new child-dose HIV tablet
In Summary

Our ultimate goal is to actively help build healthy communities worldwide through innovative and impactful healthcare solutions and partnerships.
Thank you!

Contact us at JanssenGPH@its.jnj.com

Dr. Maik Stumpf
Director Disease Management Programs
Janssen Global Public Health

Aug 31st 2015